Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (August 2021)
18 slides from Imugene's investor presentation, Aug 5, 2021
Slide 1: Imugene & Celularity Research Partnership
For personal use only ASX: IMU IMUGENE & CELULARITY RESEARCH PARTNERSHIP 5th August 2021
Slide 2: Disclaimer
Disclaimer For personal use only 1. The information in this presentation does not constitute personal investment 4. Neither the Company nor any of its directors, officers, employees, advisers, advice. The presentation is not intended to be comprehensive or provide all associated persons or subsidiar
Slide 3: Introduction to Imugene
Introduction to Imugene For personal use only AUG 2021 Imugene is a biotech company 2018 Strategic Partnership headquartered in Australia and Licensed extensive B cell with Celularity publicly traded on the Australian portfolio and platform from OSU and Mayo Clinic M AY 2 0 21 Securities Exchange (A
Slide 4: Partnership Highlights
Partnership Highlights For personal use only • Strategic Research Partnership with Celularity Inc. (Nasdaq: CELU) for the Treatment of Solid Tumors • Collaboration will explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytic) and Celularity’s CD-19-targe
Slide 5: Robert (Bob) J. Hariri, M.D., Ph.D.
• Dr. Hariri is the chairman, founder, and chief executive officer of Celularity, Inc., (NASDAQ: CELU). • Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the
Slide 6: The Next Evolution in Cellular Medicine
For personal use only THE NEXT EVOLUTION IN CELLULAR MEDICINE
Slide 7: Celularity: Company History
CELULARITY: COMPANY HISTORY Celgene Spin-out (2017) Leveraging 20+ Years of Cellular Therapeutics Innovation For personal use only Celularity and Celularity GX Acquisition and GX FIH Genetically Corp. Announce close cryopreserved Allogeneic -modified Merger merger and Allogeneic Celgene & allogeneic
Slide 8: About Celularity
About Celularity Next Evolution in Off-the-shelf Allogeneic Cellular Therapies, at Greater Scale & Quality with Attractive Economics For personal use only To harness the placenta’s unique biology and ready availability to develop therapeutic solutions Lead the evolution in placental-derived therapeu
Slide 9: Celularity IMPACT Platform
CELULARITY IMPACT™ PLATFORM Capitalizing on the Benefits of Placental-Derived Cells to Target Multiple Diseases For personal use only INHERENT ADVANTAGES OF PLACENTAL-DERIVED CELLS HEMATOLOGICAL ü Abundant and evergreen starting cell source for MALIGNANCIES allogeneic off-the-shelf therapies ü High
Slide 10: Pipeline Overview
PIPELINE Overview For personal use only CELL TYPE PROGRAM INDICATION 2021 2022 Program Milestones B-Cell IND CAR-T CyCART-19 Phase I Phase II Malignancies Submission CYNK-001 § 2H21: Dose Selection & Initiation of Expansion Cohorts (AML) Unmodified § 2H21: Establish Phase II Dose CYNK-001 Acute Myel
Slide 11: CyCART-19 Overview
CyCART-19 OVERVIEW Celularity Approach and Advantages RATIONALE CAR-T THERAPIES For personal use only § Rationale for greater stemness, expandability, persistence Cell Therapy OTHER CELULARITY § Abundant renewable starting cell source for allogeneic therapies AUTOLOGOUS Technology Scorecard ALLOGENE
Slide 12: CyCART-19 Demonstrates Greater Anti-Lymphoma Activities & Survival
CyCART-19 DEMONSTRATES GREATER ANTI-LYMPHOMA ACTIVITIES & SURVIVAL Enhanced Efficacy & Persistence, Prolonged Immune Attack upon Tumor Recharging For personal use only Survival CyCART: Durable Persistence 1 0 0 R e - c h a lle n g e 8 0 (d 1 2 2 ) S u r v iv a l 6 0 4 0 2 0 0 0 3 0 6 0 9 0 1 2 0 1 5
Slide 13: The CAR T Solid Tumour Challenge & Imugene's Solution
The CAR T Solid Tumour Challenge & Imugene’s Solution NEW CONCEPT For personal use only Chimeric Antigen Receptor (CAR) T cell therapy has had limited activity in solid tumours, largely due to a lack of selectively and highly expressed surface antigens, such as the blood B cell antigen Utilise OV’s
Slide 14: Mechanism of Action: How does it work?
Mechanism of Action: How does it work? For personal use only onCARlytics makes solid tumours “seen” by CD19 directed CAR T 1 1. OnCARlytics infects tumour cells 4 2. Virus replication and production of CF33-CD19 on the cell surface 2 enabling CD19 CAR T cell targeting 3. Tumour cell lysis leads to v
Slide 15: onCARlytics delivers CAR Targets to solid tumours
% 37.8%<1% 6.8% 63.8% 11.5%; this version22.2% 98.0% 37.8% 63.8% 98.0% bioRxiv preprint doi: https://doi.org/10.1101/843052 posted November 16, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without pe
Slide 16: onCARlytics and CyCART-19 - a perfect match
onCARlytics and CyCART-19 - a perfect match! For personal use only 9 CA RT-1 Cy 1. 2. 3. 4. CD19 ONCOLYTIC VIRUS CD19 ONCOLYTIC VIRUS CyCART-19 CELLS CANCER CELLS DIE INFECTS SOLID CANCER CAUSES THE SOLID RECOGNISE THE “CD19 CELLS CANCER CELLS TO GROW FLAGS” AND ATTACK THE “CD19 FLAGS” CANCER CELL 1
Slide 17: Milestones
Milestones For personal use only Technology Milestone onCARlytics 1st Patient Dosed Monotherapy Next 12-24 months onCARlytics FDA IND Clearance PD1-Vaxx Combination RP2D onCARlytics GLP Toxicology Study VAXINIA 1st Patient Dosed PD1-Vaxx Expansion combination study FPI HER-Vaxx Phase 2 Final Analysi
Slide 18: Leslie Chong, Managing Director & CEO
For personal use only Leslie Chong Managing Director & CEO leslie.chong@imugene.com